RBC Capital Reaffirms Their Buy Rating on IGM Biosciences (IGMS)
In a report released on November 8, Brian Abrahams from RBC Capital maintained a Buy rating on IGM Biosciences (IGMS – Research Report), ...
Biotech firm backs off its focus on oncology research
IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...
Cautious Outlook for IGM Biosciences Amid Delayed Data and Financial Adjustments
Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of ...
Yahoo Finance6d
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...
manilatimes7d
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
Cellectar's lead product candidate, iopofosine I 131, is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate. Iopofosine I 131 is an ...
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
Since it has a market capitalisation of US$939m, IGM Biosciences' US$176m in cash burn equates to about 19% of its market value. As a result, we'd venture that the company could raise more cash for ...
Non-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...
Zacks.com on MSN14d
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.90 per share a year ago. These ...
Frontiers17d
Clones reactive to apoptotic cells and specific chemical adducts are prevalent among human thymic B cells
Additionally, thymic IgM B cells reactive to adducts were more likely to recognize ... and filtered through a 40 μm cell strainer (BD Biosciences). Thymocyte cell suspensions were then cryopreserved ...
Yahoo Finance20d
iShares Exp and ed Tech Sector (^IGM-IV)
The US presidential election is just over a week away. Market (^DJI, ^IXIC, ^GSPC) volatility linked to electoral uncertainty has emerged as a key concern for investors. However, Federated Hermes ...
GlobalData on MSN20d
Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments
The funds will be used to advance Agomab’s candidates through clinical trials, including AGMB-129 for patients with ...
Morningstar20d
IGM Biosciences Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...